Document is current
Any future updates will be listed below
-
Authors
Dong, Shihua
Yang, Zhicong
Xu, Peng
Zheng, Wanxiang
Zhang, Baolong
Fu, Fangqiu
Mao, Zhanrui
Yuan, Jianlin https://orcid.org/0000-0001-9166-3528
Chen, Haiquan
Yu, Wenqiang
- License Information
-
More Information
Article History
Received: 4 January 2022
Revised: 26 April 2022
Accepted: 9 May 2022
First Online: 6 July 2022
Competing interests
: S.D. is one of the co-founders and the R&D director of Shanghai Epiprobe Biotechnology Co., Ltd. W.Y. serves on the scientific advisory boards of Epiprobe. P.X. and Z.M. are employees of Epiprobe. All other authors declare no competing interests.
: All samples were collected from Xijing Hospital of Air Force Medical University and Fudan University Shanghai Cancer Center. The study was approved by the Ethics Committee of the First Affiliated Hospital of the Air Force Medical University (License Number: KY20193133) and Ethics Committee of the Fudan University Shanghai Cancer Center (License Number: 050432-4-1911D). Informed consent was acquired from all patients and control subjects.
